This company has shut down. Embark Biotech is no longer operating — its last tracked round was a Convertible Note in 2021.
Explore the Startup GraveyardEmbark Biotech is a biotech company identifying cell surface receptors regulating fat tissue calorie-burning and glucose and lipid uptake.
Embark Biotech has raised $1.6M in total funding. The most recent round was Convertible Note. The last funding was announced in September 2021.
Embark Biotech's investors include BioInnovation Institute.
Embark Biotech is headquartered in Copenhagen, Denmark.
Embark Biotech is a biotech company identifying cell surface receptors regulating fat tissue calorie-burning and glucose and lipid uptake.
Embark Biotech is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Embark Biotech — Funding & Investors." VCBacked, September 23, 2021, https://www.vcbacked.co/company/embark-biotech. Accessed August 14, 2026.
VCBacked. (2021). Embark Biotech — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/embark-biotech
{{cite web |title=Embark Biotech — Funding & Investors |url=https://www.vcbacked.co/company/embark-biotech |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated